Loading...
Loading...
THRD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 10.7M |
| Operating I/L | -10.7M |
| Other Income/Expense | -0.0M |
| Interest Income | 3.2M |
| Pretax | -7.6M |
| Income Tax Expense | -3.2M |
| Net Income/Loss | -7.6M |
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development of medicine for allergic and inflammatory diseases. Their flagship product, THB001, is an oral small-molecule KIT inhibitor designed to treat chronic urticaria, a dermatologic condition characterized by mast cell activation. This innovative treatment targets red, itchy, painful welts, or hives, and also shows promise for airway and gastrointestinal tract indications.
